Sounds totally voluntary on the company's part. From what the CEO said on the recent investment show, the company wants to get out front with the FTC on claims it's going to advertise for Acquiprin; i.e. the absorbency rate, etc. IR said that most of the claims have already been substantiated, so proving them won't be a problem. So documenting the proof of the claims through claims testing will be huge when they start marketing the product to the public.
News 
Market Data 
Discover 
AI
